Hemanext is a privately held medical technology company dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs).

Supporting the AABB Community:

Our thoughts are with the residents, victims, and all those that Hurricane Ian has impacted.  Despite not being able to support AABB in person at the Annual Meeting, we will do so remotely at the virtual meeting on November 6-7 and look forward to the live event in 2023.

Our Commitment:


AABB Corporate Partner Spotlight

For more than a decade, Hemanext has committed its resources to the transfusion medicine community through its investments and its research — research that has garnered several National Institutes of Health grants worth $8.2 million and AABB’s RISE Award in 2021.


AABB’S CORPORATE PARTNER PROGRAM focuses on celebrating the vital work of corporate members of the blood and biotherapies community.

Learn More About Hemanext

Corporate Hemanext Video

Educational Symposiums

Patient Advocacy Groups